Morris, H; Wallach, J. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 614-632. 942 kB. https://doi.org/10.1002/dta.1620 #3-MeO-PCMo
Colestock, T; Wallach, J; Mansi, M; Filemban, N; Morris, H; Elliott, SP; Westphal, F; Brandt, SD; Adejare, A. Syntheses, analytical and pharmacological characterizations of the ‘legal high’ 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues. Drug Test. Anal., 1 Feb 2018, 10 (2), 272-283. 1.3 MB. https://doi.org/10.1002/dta.2213
EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB. #58
Wallach, J; Brandt, SD. Phencyclidine-based new psychoactive substances. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 261-303. 515 kB. https://doi.org/10.1007/164_2018_124 #3-MeO-PCMo
Ortiz, DMD; Kim, M; Lee, HJ; Botanas, CJ; Custodio, RJP; Sayson, LV; Campomayor, NB; Lee, C; Lee, YS; Cheong, JH; Kim, HJ. 4-F-PCP, a novel PCP analog ameliorates the depressive-like behavior of chronic social defeat stress mice via NMDA receptor antagonism. Biomol. Ther., 1 Mar 2023, 31 (2), 227–239. 5.7 MB. https://doi.org/10.4062/biomolther.2022.159 #3-MeO-PCMo
1-(β-Methyl-α-propyl-3,4-methylenedioxyphenethyl)pyrrolidine · BM-MDPV
4-HO-2-Me-PCMo · Hydroxy-methyl-PCMo
Metethoheptazine · WY-535